Under the global exclusive license deal, Kumquat will be responsible for the Phase 1a study of its inhibitor and Bayer will ...

Bayer & Kumquat Biosciences enter global license and collaboration to develop and commercialize Kumquat’s KRAS G12D inhibitor: Berlin, Germany Wednesday, August 13, 2025, 11:00 ...

Ever since joining Sevilla on loan in January 2023, centerback Loic Bade has stood as a crucial component to the Spanish club ...

BERLIN (Reuters) -German pharmaceutical group Bayer announced on Tuesday a deal worth up to $1.3 billion with Kumquat ...

After 23 goals and 24 assists in 142 appearances across all competitions for Bayer Leverkusen during a four year spell, Amine ...

Bayer has teamed up with Kumquat Biosciences for a juicy opportunity, committing up to $1.3 billion for the global license to ...

Bayer will partner with Kumquat Biosciences to develop Kumquat’s KRAS G12D inhibitor, which could generate $1.3 billion-plus for the San Diego biotech.

For $1.3 billion in aggregate—including upfront and milestone payments—Bayer will get exclusive global access to Kumquat ...

Investor concerns that Bayer's earnings were inflated by soccer player transfer fees rather than supported by its core ...

Another Massachusetts biotech has reached the end of the road. | Another Massachusetts biotech has reached the end of the ...

An announcement from Board of Education President Steven Blair on Friday said Mike Dominguez resigned July 31 to "pursue ...